Bayer files for EU approval of gadoquatrane
Submitted dose corresponds to 60% gadolinium reduction compared to standard macrocyclic agents
This website uses cookies to give our readers the best website experience. Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.